the aid library

LIST OPTIONS

Filter

4535

Sort by:

Direction:

Download (11442)

View PDF (2289)

Sterilization Manual for Health Centers

Silvia I. Acosta-Gnass and Valeska de Andrade Stempliuk PAHO; USAID (2009) C_WHO

Download (561)

View PDF (3191)

Une meilleure gestion des déchets d’activités de soins

Rushbrook, R.; Zghondi, R. OMS; Banque Mondiale (2005)

Download (578)

View PDF (1959)

Règlement sanitaire international (2005) Domaines de travail pour la mise en oeuvre du Règlement

Organisation de la Santé Mondiale (2007)

Download (1644)

View PDF (1812)

Règlement sanitaire international (‎2005)‎ : outil d’autoévaluation pour l’établissement de rapports annuels par les états parties, 2e ed

Organisation de la Santé Mondiale (2022) C_WHO

Download (1018)

View PDF (2511)

Framework towards tuberculosis elimination in low-incidence countries

World Health Organization (2014) C_WHO

This Framework offers a coherent approach for eliminating tuberculosis (TB) in low-incidence countries. It is designed to guide national policy-makers and those responsible for technical aspects of the national TB response in accelerating efforts towards elimination. The document will also be inform... more

Download (196)

View PDF (222)

Contrôle des épidémies de méningite en Afrique

Organisation mondiale de la Santé (2015) C_WHO

Guide de référence rapide à l’intention des autorités sanitaires et des soignants Révisé en 2015

Download (1285)

View PDF (3011)

Tool for the assessment of injection safety

World Health Organization (2001) C_WHO

Download (927)

View PDF (1572)

Community-Based Care for Drug-Resistant Tuberculosis: A Guide for Implementers

United States Agency for International Development (USAID) (2011)

This guide provides practical, step-by-step guidance on how to organize, implement, and monitor community-based care for DR TB. It is equally useful for program planning or supervision. The target audience for this guide is TB Program Managers, governments, policy makers, nongovernmental organizatio... more

Download (342)

View PDF (467)

Africa, WASH, and the Millennium Development Goals: A Local Systems Case Study of How Senegal Achieved MDG Target 7c

McGahey, Christopher USAID (2017) C1

Nationally, Senegal met the MDG target for water supply access. It did this by engaging the public and private sectors to effectively invest and report on investments. It focused on larger population centers, less on remote regions of the country. Its achievements set the stage for more equitable an... more

Download (287)

View PDF (486)

Africa, WASH, and the Millennium Development Goals: A Local Systems Case Study of How Ethiopia Achieved MDG Target 7c

McGahey, Christopher USAID (2017) C1

Ethiopia met the MDG target for drinking water access with a unique and high degree of success. The magnitude of the country’s success in providing improved drinking water to nearly half of its population in 25 years despite its diversity, size, and challenges cannot be overstated. This case study... more

Download (2305)

View PDF (5539)

Contrôle de l´infection en cas de fièvre hémorragique virale en milieu hospitalier africain

Organisation Mondiale de la Santé OMS; CDC (1998)

Download (623)

View PDF (1351)

Guidelines for surveillance of drug resistance in tuberculosis

World Health Organization (2021) C_WHO

6th edition

Download (1145)

View PDF (2065)

Limited Access Humanitarian Programming

Sandisan, P. Oxfam (2017) C1

Operational guidance for managing programme quality. These guidelines are about implementing the programme-quality standards of the Core Humanitarian Standard in limited access humanitarian response. They have been developed using approaches and tools tested by Oxfam, other INGOs and the UN in Afgh... more

Download (264)

View PDF (333)

External Quality Assessment for AFB Smear Microscopy

CDC, KNCV, RIT, PHL, et. al (2017) C2

Accessed November 2017.

Download (92)

View PDF (130)

Strategic Considerations for Mitigating the Impact of COVID-19 on Key Population-Focused HIV Programs

FHI 360; UNAIDS reliefweb (2020) C2

The COVID-19 pandemic has affected everyone, including key populations at higher risk of HIV. And the gains made against other infectious diseases, including HIV, are at risk of being reversed as a result of disruptions caused by COVID-19. This is the background to a new report published by FHI 360,... more

Download (139)

View PDF (173)

Standard operating procedures for surveillance of meningitis preparedness and response to epidemics in Africa

World Health Organization WHO (2018) C_WHO

Epidemic meningitis is a major public health challenge in the African 'meningitis belt', an area that extends from Senegal to Ethiopia with an estimated total population of 500 million. Since 2002, the World Health Organization (WHO), in collaboration with its collaborating centres for meningitis, h... more

Download (47)

View PDF (547)

Fabrication, sécurité et contrôle qualité des vaccins

Organisation Mondiale de la Santé OMS (2020) C_WHO

Cet article fait partie d’une série d’explications à propos de la mise au point et de la distribution des vaccins.

Download (84)

View PDF (115)

Plan Estratégico para la vacunación contra la COVID-19 en Argentina

Ministerio de Salud Argentina Ministerio de Salud Argentina (2020) CC

Strategic Plan for COVID-19 vaccination in Argentina

Download (17)

View PDF (13)

STAR-H: Strategic Toolkit for Assessing Risks in Health Facilities

Pan American Health Organization (2023) CC

Health facilities in the Region of the Americas frequently suffer the effects of health emergencies and disasters, which jeopardize their ability to provide services to the population. The STAR-H methodology helps staff responsible for health emergency and disaster risk management to identify and as... more

Download (245)

View PDF (328)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more